Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Developing next-generation engineered cell therapies targeting solid tumors.
Oncology
Technology Platform
A proprietary cell engineering platform that enhances T cell trafficking, persistence, and function within the solid tumor microenvironment.
Opportunities
Addressing the vast unmet need in solid tumor treatment with a potentially best-in-class cell therapy platform.
Risk Factors
Clinical risks include managing cytokine release syndrome and neurotoxity, alongside the scientific challenge of tumor heterogeneity and antigen escape.
Competitive Landscape
Operates in the crowded solid tumor cell therapy space, competing with numerous biotechs and pharma companies developing enhanced CAR-T and TCR therapies.